Claims
- 1. A compound of Formula (I):
- 2. The compound of claim 1, wherein Ring A is optionally substituted with halo, —C1-C4 alkyl, —C1-C4 alkoxy, —C1-C4 haloalkyl, C1-C4 haloalkoxy, —C1-C4 acyl, amido, substituted amido, —NO2, —CN, —OH, —NH2 and substituted amino; Y is —C(R4R5) or C═O; Z is ═O; R1 is —H; R2 is a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group; R3 is a substituted or unsubstituted aryl group; and X is —C(R4R5)—, —N(R4)—, —C(═O)— or —O—.
- 3. The compound of claim 2, wherein Y is C═O; R2 is an unsubstituted aryl group or an aryl group substituted with lower alkyl, amido, cyano, or halo; R3 is a substituted or unsubstituted phenyl, a substituted or unsubstituted pyridyl or a substituted or unsubstituted thienyl; and X is —CH2—, —CH(lower alkyl)-, —NH—, —N(lower alkyl)-, —C(═O)— or —O—.
- 4. The compound of claim 1 of Formula (Ia):
- 5. The compound of claim 4, wherein Ring A is optionally substituted with lower alkyl, Z1 and Z2 are each ═O; R1 is —H; R2 is a substituted or unsubstituted aryl group or a substituted or unsubsituted non-aromatic heterocylic group; R3 is a substituted or unsubstituted aryl group; and X is —C(R4R5)—, —N(R4)—, —C(═O)— or —O—.
- 6. The compound of claim 5, R2 is an unsubstituted aryl group or an aryl group substituted with lower alkyl, amido, cyano, or halo; R3 is a substituted or unsubstituted phenyl, a substituted or unsubstituted pyridyl or a substituted or unsubstituted thienyl; and X is —CH2—, —CH(lower alkyl)-, —NH—, —N(lower alkyl)-, —C(═O)— or —O—.
- 7. A compound of claim 1 of Formula (Ib):
- 8. The compound of claim 7, wherein each R21 is independently H, OH, F, or Cl; R22 is optionally substituted aryl; and R23 is H; and X′ is CH2.
- 9. The compound of claim 8, wherein R22 is phenyl optionally p-substituted with lower alkoxy, OH, CN, F, Cl, Br, I, NO2, NH2, C(O)NH2, CO2H, or CO2R′.
- 10. A compound selected from Compound 1-Compound 64.
- 11. A pharmaceutical composition comprising at least one compound according to any one of claims 1-10 and a pharmaceutically acceptable carrier.
- 12. The pharmaceutical composition of claim 11, further comprising one or more additional therapeutic agents.
- 13. The pharmaceutical composition of claim 12, wherein the additional therapeutic agent is an agent against cancer agent, an autoimmune disease, an inflammatory disorder or pain.
- 14. A method for treating cancer, an inflammatory disorder or an autoimmune disease comprising the step of administering to a subject in need thereof an effective amount of the pharmaceutical composition according to any one of claims 11-13.
- 15. A method for preventing cancer, an inflammatory disorder or an autoimmune disease comprising the step of administering to a subject in need thereof an effective amount of the pharmaceutical composition according to any one of claims 11-13.
- 16. A method for preventing or treating a disorder involving PDE4 or elevated levels of cytokines comprising the step of administering to a subject in need thereof an effective amount of the pharmaceutical composition according to any one of claims 11-13.
- 17. The method according to claim 16, wherein the disorder is characterized, mediated or exacerbated by overproduction or activity of TNFα.
- 18. The method according to claim 16, wherein the disorder is characterized, mediated or exacerbated by overproduction or activity of PDE4.
- 19. A method of inhibiting TNFα or PDE4 in a cell comprising the step of contacting the cell with an effective amount of a compound according to any one of claims 1-10.
- 20. A method for reducing TNFα levels in a subject comprising administering to the subject an effective amount of a compound according to any one of claims 1-10.
- 21. A method for suppressing inflammatory cell activation comprising the step of contacting the cell with an effective amount of a compound according to any one of claims 1-10.
- 22. The use of a compound according to claim 1 for the manufacture of a medicament for the prevention or treatment of cancer, an inflammatory disorder, an autoimmune disease or other condition involving PDE4 or elevated levels of cytokines, wherein the medicament comprises an effective amount of the compound.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Utility application Ser. No. 10/319,401, filed Dec. 12, 2002, which, in turn, claims the benefit of U.S. Utility application Ser. No. 10/244,088, filed Aug. 27, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60322020 |
Sep 2001 |
US |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
10319401 |
Dec 2002 |
US |
Child |
10388332 |
Mar 2003 |
US |
Parent |
10244088 |
Sep 2002 |
US |
Child |
10319401 |
Dec 2002 |
US |